Articles tagged with Cancer Medication
A recent study published in Lancet Oncology has found that measuring blood hormone levels can identify post-menopausal women who are most likely to benefit from anastrozole, a medication used to prevent breast cancer. The study suggests that inexpensive blood tests could be used to personalize preventive therapy for these women.
Researchers from Japan have discovered a novel targeted molecular therapy using microRNA-451a to suppress the progression of gemcitabine-resistant biliary tract cancers. The study found that miR-451a significantly diminished cell proliferation, induced cell death, and reduced chemoresistance in cancer cells.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
A new study at the University of Turku discovered that plixorafenib inhibits multiple signaling pathways in cutaneous squamous cell carcinoma, showing promise for treatment. The drug was originally developed for melanoma and lung cancer, but its effectiveness against cSCC is significant.
A phase 2 trial found that durvalumab is safe and may benefit overall survival in non-small cell lung cancer patients with borderline performance status. The study also showed stable quality of life and a lower incidence of severe treatment-related adverse events compared to platinum doublet chemotherapy.
Researchers investigate nanoparticles for cancer treatment, hoping to reduce side effects and improve efficacy. La-Beck's lab aims to understand the body's interaction with nanoparticles and their impact on tumor growth and immune responses.
Researchers at Radboud University Medical Center found that redispensing unused cancer medications can result in significant cost savings and reduced waste. The study, published in JAMA Oncology, suggests that by reissuing up to two-thirds of wasted medicine packaging, annual savings could amount to tens of millions of euros.
Researchers at UNC School of Medicine have pieced together the lesser-known DNA repair pathway, polymerase theta-mediated end joining (TMEJ), which is upregulated in patients with hereditary breast cancer, ovarian cancer, and prostate cancer. The discovery could lead to new therapies for cancer by targeting this pathway.
Researchers at Hokkaido University found that cancer stem cells cause macrophages to age, suppressing their antitumor activity. Supplementing mice with nicotinamide mononucleotide restored macrophage function and prevented tumor growth.
Researchers found that people with overweight or obesity who took semaglutide for over 3 years had a 20% lower risk of heart attack, stroke, or death from cardiovascular disease. The study showed significant weight loss and improved cardiovascular outcomes in adults without diabetes.
Experts call for urgent measures to address discrimination against patients fleeing war or conflict zones, those with serious mental illnesses, and frail elderly patients. Guidelines for treating advanced breast cancer should prioritize patient preferences and involve multidisciplinary care teams.
Researchers identified key factors in DNA repair, revealing the 'proofreading' portion of polymerase epsilon helps prevent strand breakage. This knowledge arms scientists with ways to enhance anti-cancer drug effectiveness and develop new diagnostic methods.
A drug currently in clinical trials as a cancer therapy can also stimulate pancreatic beta cells to secrete insulin, revealing a new mechanism for insulin regulation in type 2 diabetes. The preclinical discovery provides a new chemical tool for probing the biology of diabetes and could lead to better treatments.
Researchers at IRB Barcelona have identified the mechanism by which the MAF protein promotes breast cancer metastasis, revealing a key interaction with the estrogen receptor. This finding opens up new therapeutic options for patients with high MAF levels, who may benefit from treatments aimed at preventing metastases.
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
Researchers developed a new class of drugs targeting PRMT5 enzyme, exploiting genetic vulnerability in tumor suppressor genes. Early clinical trials show promising results for patients with specific types of cancer, including melanoma and mesothelioma.
CNIO researchers have discovered a previously unknown mechanism of action for the first oncogene, c-Src. The study reveals that c-Src can autonomously activate itself through autophosphorylation, leading to cancer formation. This finding has significant implications for the development of new drugs targeting this enzyme.
A new cancer immunotherapy that targets two immune-evading tumor tactics has shown promising results in an early clinical trial. The drug, tebotelimab, blocks both PD-1 and LAG-3 proteins, leading to a double-digit response rate in patients with advanced solid tumors or blood cancers.
The study found that precision oncology therapies require genomic biomarker screening for patient selection and have expanded over the years. The analysis showed a slow expansion in approvals from 1998 to 2017 and a rapid increase from 2017 to 2022, with 86 out of 198 approved drugs classified as precision oncology drugs.
Researchers identified YB-1 as an attractive therapeutic target for pleural mesothelioma, a cancer caused by asbestos exposure. Indirect targeting of YB-1 via histone deacetylase inhibitors showed promise in enhancing chemo- and radiotherapy sensitivity.
A new cancer drug candidate has been found to restore the effectiveness of the immune system in fighting tumors, including melanoma, bladder cancer, leukemia, and colon cancer. The drug works by lowering a toxic compound called MTA, which impairs normal functioning of immune cells and blocks immunotherapies.
Researchers at Scripps Research have identified promising cancer drug targets by combining precise genome engineering and protein activity profiling. They used base editing to alter thousands of possible drug targets, then integrated the data with chemical proteomic information to pinpoint hundreds of potential targets.
Researchers have developed a novel zebrafish xenograft platform to screen for novel treatments for glioblastoma, an aggressive brain tumor. The platform uses zebrafish avatars to model glioblastoma cells from individual patients, allowing researchers to identify patient-specific targets and potential treatments.
Armida Labs, a UCR-founded pharmaceutical company, has received a $400,000 NIH Small Business Innovation Research grant to develop its breakthrough pancreatic cancer therapy Targefrin. The grant will enable the company to gather industry-standard data for human clinical trials.
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
Researchers at MedUni Vienna discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of P-glycoprotein, opening new possibilities for delaying relapse. This breakthrough could represent a step forward in treating aggressive triple-negative breast cancer, which has limited treatment options and ...
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
Researchers combined three highly potent cancer drugs in a single prodrug that is activated in tumor cells, resulting in improved efficacy and reduced side effects. The new approach has shown promise as a potential solution to reduce the burden on patients' bodies during cancer treatment.
A study found that 80.3% of patients with metastatic breast cancer who received standard care treatment with alpelisib developed hyperglycemia, with 40.2% experiencing serious hyperglycemia. Lifestyle interventions and medication may help improve blood sugar levels and reduce the risk of needing to discontinue the drug.
Researchers at Linköping University develop a new method to deliver strong compounds specifically to bacteria, allowing for efficient and safe treatment of infections. The TOUCAN strategy uses nucleases to target bacterial DNA, reducing side effects associated with current antibiotics.
University of Queensland researchers have identified a novel molecule that could overcome cancer drug resistance and prevent tumour regrowth in cancer patients. The newly discovered molecule is not currently a target for treatment, opening the potential for new drug development to combat this major cause of death in cancer patients.
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
Researchers at City University of Hong Kong have developed a new class of near-infrared-activated photo-oxidants that can effectively kill cancer cells without requiring oxygen. The discovery offers a promising direction for developing anti-cancer drugs and could overcome existing limitations of photodynamic therapies.
A study published in the Chinese Medical Journal reveals that methotrexate can be an effective treatment for liver cancer with a specific genetic mutation. The drug works by disrupting nucleotide synthesis in cancer cells, making it a promising alternative to current first-line treatments.
Researchers have discovered two FDA-approved and EMA-approved drugs that inhibit prmt5, a protein linked to promoting tumor growth in several cancers. These repurposed drugs show promise in reducing cancer cell proliferation and tumor growth.
Researchers discuss new drugs available for HER2-positive breast cancer patients with brain metastasis, showing improved outcomes and quality of life. The development of targeted therapies has led to better survival rates among these patients.
A recent study published in PLOS Biology suggests that chemotherapy injury to surrounding non-cancer cells can awaken dormant breast cancer cells, promoting cancer growth and recurrence. The researchers found that the release of specific cell signaling molecules, G-CSF and IL-6, by injured stromal cells drives this process.
Researchers at UTSA are studying the bioactive properties of Sweet Annie, a plant used in traditional Chinese medicine for over 2,000 years. The study reveals that arteannuin B from the plant has anti-COVID and anti-glioblastoma properties, offering new avenues for targeted therapy.
Salk researchers have identified a new set of molecules that fuel the growth of tumors in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The study found that activating a super-enhancer leads to an increase in protein production, enabling rapid cell growth.
A free online tool can help prostate cancer patients save thousands of dollars in out-of-pocket drug costs by comparing Medicare Part D prescription plans. The Medicare Part D Plan Finder identifies significant savings for patients taking abiraterone or enzalutamide, two common prescription drugs for advanced prostate cancer.
Researchers at Technion-Israel Institute of Technology developed an AI tool to identify powerful drug combinations that significantly enhance cancer treatment. The 'meta-synergy' approach uses artificial intelligence and text mining to find optimal pairs of drugs, resulting in highly effective nanomedicines with fewer side effects.
Breast cancer survivors often struggle to take their life-extending medication due to side effects and high costs. A new study found that interventions such as cost-cutting policies, mobile apps, and psychological counseling can increase medication adherence by nearly 1.5 times. Addressing mental health issues, particularly depression,...
Researchers found that antioxidants activate a mechanism forming new blood vessels in tumor cells, which can help them grow and spread. The study suggests that dietary supplements containing antioxidants may accelerate tumour growth and metastasis in cancer patients.
A new study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer. The treatment improved survival...
A new study finds that cost-cutting policy changes, mobile apps, and psychological strategies can increase medication adherence by nearly 1.5 times among breast cancer survivors. The study also highlights the importance of managing side effects through physical therapy, exercise, and behavioral counseling.
Researchers Elzbieta Izbicka and Robert T. Streeper discuss the evolution of cancer drug development, highlighting recent progress and emerging challenges due to environmental factors. They also examine how artificial intelligence may impact future drug development.
A new study finds that integrating longitudinal tobacco cessation care into lung cancer screening improves quit rates and enhances the benefits of screenings. Researchers recommend incorporating behavioral treatment and medication into the screening process to help smokers quit.
A team of KAUST researchers has found a critical protein that regulates cell division and proliferation in breast cancer and leukemia. Their work clears the way for the development of targeted drugs by refuting recent challenges to their approach.
A new gene therapy study has identified microRNA-22 as a potential treatment for liver cancer, achieving better survival outcomes and reducing inflammation compared to the current FDA-approved drug lenvatinib. The treatment was administered via a single intravenous injection and showed no observable toxicity.
Researchers have found that a prostate cancer drug called proxalutamide can block SARS-CoV-2 viral entry and reduce inflammation. The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.
Researchers found a combination of ipilimumab and nivolumab can extend progression-free survival and improve response rates in patients with resistant metastatic melanoma. The treatment showed a 37% improvement in progression-free survival compared to ipilimumab alone.
Chronic disease medications impair the body's ability to regulate core temperature, increasing the risk of heat-related illness in elderly patients. Exercise and improved fitness levels can help mitigate these effects, but bodily impairments from chemotherapy and medications may limit exercise capacity.
A study by the University of Gothenburg found that many expensive cancer drugs have unclear patient benefits, with only one drug showing both increased life expectancy and improved quality of life. The researchers emphasize the need for further discussions on drug approvals to ensure effective use of limited healthcare resources.
Scientists at Oak Ridge National Laboratory are developing new cancer treatments that target the metabolic pathway hijacked by cancer cells. Using neutrons and x-rays, researchers mapped the enzyme structure to design roadblocks along the pathway.
A new study has discovered that metformin, a common diabetes medication, can significantly slow the progression of STAT3-positive prostate cancer. The research team identified the key factors regulating tumour cell growth and found that permanent activation of STAT3 prevents prostate cancer development and metastasis.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
Researchers highlight the need for effective treatment strategies for adenoid cystic carcinoma (ACC) of the head and neck, which is a highly malignant tumor with variable localizations. Proton therapy shows decisive advantages in long-term survival rates for ACC.
Researchers propose disease-oriented dosing of rapamycin to delay age-related diseases and increase lifespan. By decelerating early development of these diseases, rapamycin may help individuals live longer.
Researchers at Insilico Medicine discovered novel inhibitors for salt-inducible kinase 2 (SIK2), a potential target for anti-inflammation and anti-cancer therapy. The findings were published in the July 13 edition of Bioorganic & Medicinal Chemistry, demonstrating the power of Insilico's Pharma.AI platform.
Researchers at Queensland University of Technology have developed a new approach to designing molecular ON-OFF switches based on proteins, which can be used in various biotechnological and biomedical applications. The novel technique allows for faster and more accurate diagnostic tests for detecting diseases and monitoring water quality.